In children evaluated for a possible macrolide allergy, intradermal testing with a suspected culprit drug at 0.05 mg/mL showed high specificity (92.7%) but limited sensitivity. To confirm an allergy ...
NanoPass Technologies Ltd. ("NanoPass"), a pioneer in intradermal delivery solutions for vaccines, announced today that it has entered into a license agreement for the supply of MicronJet600™, its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback